bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Yan Zi-Xun , Li Li , Wang Wen , OuYang Bin-Shen , Cheng Shu , Wang Li , Wu Wen , Xu Peng-Peng , Muftuoglu Muharrem , Hao Ming , Yang Su , Zhang Mu-Chen , Zheng Zhong , Li James , Zhao Wei-Li
Published: April 2023

Supplementary Figure S3. Relative mRNA expression of activating and inhibitory markers. (A) Relative mRNA expression (mean {plus minus} SD) of activating markers in the complete remission (CR) and partial remission (PR) group. (B) Relative mRNA expression (mean {plus minus} SD) of inhibitory markers in the CR and PR group. Student's t-test, one-way ANOVA, Wilcoxon signed-rank test or Friedman test was used, as appropriate. SD: Standard Deviation, IQR: interquartile range.
Table from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplemetary tables
Supplementary Methods from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Methods
Supplementary Figure 5 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 5
Supplementary Figure 1 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 1
Table S2 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Table S2
Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 6
Figure S4 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Figure S4
Supplementary Data from Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis
Authors: Saini Neeraj , Ma Junsheng , Milton Denái R. , Patel Romil , Varma Ankur , Bashir Qaiser , Delgado Ruby , Mukherjee Akash , Rondon Gabriela , Popat Uday R. , Hosing Chitra M. , Nieto Yago , Kebriaei Partow , Alousi Amin M. , Ahmed Sairah , Tang Guilin , Mehta Rohtesh , Srour Samer , Khouri Issa F. , Iyer Swaminathan , Weber Donna M. , Thomas Sheeba K. , Lee Hans C. , Manasanch Elisabet E. , Patel Krina K. , Orlowski Robert Z. , Champlin Richard E. , Qazilbash Muzaffar H.
Published: April 2023

Supplementary Appendix
Supplementary video from Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors
Authors: Johnson S. Peter , Ogunlade Olumide , Lythgoe Mark F. , Beard Paul , Pedley R. Barbara
Published: April 2023

SW1222 subcutaneous tumor by PAT
Supplementary Table 2 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

Copy number for AR-FL, AR-V7 and ARv567es for the evaluable population at baseline AR, androgen receptor; FL, full length.
Supplementary Figure 4 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

Confirmation of ARv567es amplicon by Sanger Sequencing A) Agarose gel electrophoresis showing the PCR-amplified ARv567es amplicon using ddPCR primers. Lane 1 DNA ladder from New England Biolabs, Inc; Lane 2 HEK293 cells transfected with Empty Vector (Negative control); Lane 3 HEK293 cells transfected with ARv567es-variant plasmid (Positive control); Lane 4 HEK293 cells transfected with ARv567es-variant plasmid, but with no reverse transcriptase (Negative control); Lanes 5-6 is CTC-derived DNA from patients #7 and #4 respectively. The red arrow depicts the expected size of ARv567es amplicon. B) Representative DNA chromatogram following Sanger Sequencing with the reverse and forward primers for the ARv567es amplicon (Size = 95 bps). Data shown for patient #7 amplicon.
Supplementary Figure 3 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

Visual representation of AR-FL and AR splice variant expression per patient at baseline Data are shown as positive (green for AR-FL; red for AR-V7; blue for ARv567es) or negative (white boxes) for each transcript. AR, androgen receptor; FL, full length
Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Authors: Roeker Lindsey E. , Fox Christopher P. , Eyre Toby A. , Brander Danielle M. , Allan John N. , Schuster Stephen J. , Nabhan Chadi , Hill Brian T. , Shah Nirav N. , Lansigan Frederick , Yazdy Maryam , Cheson Bruce D. , Lamanna Nicole , Singavi Arun K. , Coombs Catherine C. , Barr Paul M. , Skarbnik Alan P. , Shadman Mazyar , Ujjani Chaitra S. , Tuncer Hande H. , Winter Allison M. , Rhodes Joanna , Dorsey Colleen , Morse Hannah , Kabel Charlene , Pagel John M. , Williams Annalynn M. , Jacobs Ryan , Goy Andre , Muralikrishnan Sivraj , Pearson Laurie , Sitlinger Andrea , Bailey Neil , Schuh Anna , Kirkwood Amy A. , Mato Anthony R.
Published: April 2023

Supplemental Figure 1.
Supplementary Information from Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma
Authors: Puerto-Camacho Pilar , Amaral Ana Teresa , Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Castillo-Ecija Helena , Ordóñez José Luis , Domínguez Saioa , Jordan-Perez Carmen , Diaz-Martin Juan , Romero-Pérez Laura , Lopez-Alvarez Maria , Civantos-Jubera Gema , Robles-Frías María José , Biscuola Michele , Ferrer Cristina , Mora Jaume , Cuglievan Branko , Schadler Keri , Seifert Oliver , Kontermann Roland , Pfizenmaier Klaus , Simón Laureano , Fabre Myriam , Carcaboso Ángel M. , Ludwig Joseph A. , de Álava Enrique
Published: April 2023

Supplementary Material & Methods, Figure Legends and Tables
Supplementary Figures from Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma
Authors: Puerto-Camacho Pilar , Amaral Ana Teresa , Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Castillo-Ecija Helena , Ordóñez José Luis , Domínguez Saioa , Jordan-Perez Carmen , Diaz-Martin Juan , Romero-Pérez Laura , Lopez-Alvarez Maria , Civantos-Jubera Gema , Robles-Frías María José , Biscuola Michele , Ferrer Cristina , Mora Jaume , Cuglievan Branko , Schadler Keri , Seifert Oliver , Kontermann Roland , Pfizenmaier Klaus , Simón Laureano , Fabre Myriam , Carcaboso Ángel M. , Ludwig Joseph A. , de Álava Enrique
Published: April 2023

Supplementary Figures
Table S4 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

4-week toxicity studies of PM on SD rats and beagle dogs.
Figure S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

PM showed anti-leukemia effects in Ph+ T315I mutation and Ph+ wild type B-ALL mouse models, and the clinical information of primary cells of Ph+ B-ALL patient samples.
Table S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Katagi Hiroaki , Louis Nundia , Unruh Dusten , Sasaki Takahiro , He Xingyao , Zhang Ali , Ma Quanhong , Piunti Andrea , Shimazu Yosuke , Lamano Jonathan B. , Carcaboso Angel M. , Tian Xiao , Seluanov Andrei , Gorbunova Vera , Laurie Kathryn L. , Kondo Akihide , Wadhwani Nitin R. , Lulla Rishi , Goldman Stewart , Venneti Sriram , Becher Oren J. , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Table S2
Figure S1 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

Baseline leukemia burden of the model mice before PM treatment and western blot analysis the levels of Ac-H3, Ac-H4 in bone marrow cells after PM treatment.
Figure S3 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Katagi Hiroaki , Louis Nundia , Unruh Dusten , Sasaki Takahiro , He Xingyao , Zhang Ali , Ma Quanhong , Piunti Andrea , Shimazu Yosuke , Lamano Jonathan B. , Carcaboso Angel M. , Tian Xiao , Seluanov Andrei , Gorbunova Vera , Laurie Kathryn L. , Kondo Akihide , Wadhwani Nitin R. , Lulla Rishi , Goldman Stewart , Venneti Sriram , Becher Oren J. , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Figure S3
Figure S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Katagi Hiroaki , Louis Nundia , Unruh Dusten , Sasaki Takahiro , He Xingyao , Zhang Ali , Ma Quanhong , Piunti Andrea , Shimazu Yosuke , Lamano Jonathan B. , Carcaboso Angel M. , Tian Xiao , Seluanov Andrei , Gorbunova Vera , Laurie Kathryn L. , Kondo Akihide , Wadhwani Nitin R. , Lulla Rishi , Goldman Stewart , Venneti Sriram , Becher Oren J. , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Figure S2
Supplementary Figures from Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Authors: Zuch de Zafra Christina L. , Fajardo Flordeliza , Zhong Wendy , Bernett Matthew J. , Muchhal Umesh S. , Moore Gregory L. , Stevens Jennitte , Case Ryan , Pearson Joshua T. , Liu Siyuan , McElroy Patricia L. , Canon Jude , Desjarlais John R. , Coxon Angela , Balazs Mercedesz , Nolan-Stevaux Olivier
Published: April 2023

Figures S1 to S16
Supplementary Data from Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
Authors: Subbiah Vivek , Anderson Pete M. , Kairemo Kalevi , Hess Kenneth , Huh Winston W. , Ravi Vinod , Daw Najat C. , Somaiah Neeta , Ludwig Joseph A. , Benjamin Robert S. , Chawla Sant , Hong David S. , Meric-Bernstam Funda , Ravizzini Gregory , Kleinerman Eugenie , Macapinlac Homer , Rohren Eric
Published: April 2023

Supplementary file: Previous therapies, Overall survival S1 : Prior therapies of patients with osteosarcoma enrolled on the Radium 223 trial. Supplementary Table S2: Adverse events in patients with osteosarcoma enrolled on the Radium 223 trial. Supplementary Figure 1: Overall survival of patients with osteosarcoma enrolled on the Radium 223 trial. Supplementary Figure 2: Correlation of % change in RECIST with relative change in LDH. Table 3: Table 1. Ra-223 dichloride Dose Escalation scheme (N=3/cohort)
Supplementary Data from BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Authors: Bhagirath Divya , Yang Thao Ly , Tabatabai Z. Laura , Majid Shahana , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: April 2023

Supplemental methods, fighure and table legends
Supplementary Data from BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Authors: Bhagirath Divya , Yang Thao Ly , Tabatabai Z. Laura , Majid Shahana , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: April 2023

Fig. S1 Induction of neuroendocrine characteristics upon enzalutamide treatment and/or androgen withdrawal of LNCaP cell line
Table S1 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Table S1
Figure S4 from BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Authors: Bhagirath Divya , Yang Thao Ly , Tabatabai Z. Laura , Majid Shahana , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: April 2023

Fig. S4 Release of oncogenic NE factors in prostate cancer EVs upon ENZ treatment
Figure S9 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S9
Figure S5 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S5
Figure S3 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S3
Figure S2 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S2
Figure S3 from Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses
Authors: Caetano Mauricio S. , Younes Ahmed I. , Barsoumian Hampartsoum B. , Quigley Michael , Menon Hari , Gao Chan , Spires Thomas , Reilly Timothy P. , Cadena Alexandra P. , Cushman Taylor R. , Schoenhals Jonathan E. , Li Ailin , Nguyen Quynh-Nhu , Cortez Maria Angelica , Welsh James W.
Published: April 2023

CD8+ CD103+ TRM cells express high levels of PD1. Flow cytometric analysis for TILs on day 29 from the triple therapy group (RT + α-PD1 + α-MerTK). Cells were gated on CD45 population then on CD4 and CD8, followed by CD8 and CD103 to check for PD1 expression in the final gate.
Figure S2 from Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses
Authors: Caetano Mauricio S. , Younes Ahmed I. , Barsoumian Hampartsoum B. , Quigley Michael , Menon Hari , Gao Chan , Spires Thomas , Reilly Timothy P. , Cadena Alexandra P. , Cushman Taylor R. , Schoenhals Jonathan E. , Li Ailin , Nguyen Quynh-Nhu , Cortez Maria Angelica , Welsh James W.
Published: April 2023

The triple therapy expresses high levels of TNF-α and IL-12 β cytokines. The NanoString results showed significant increase in IL-12 and TNF-α with the triple therapy group compared to no treatment. On the other hand, IL-6 was not significantly modulated.
Figure S12 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S12
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Authors: Leleu Xavier , Fouquet Guillemette , Richez Valentine , Guidez Stéphanie , Duhamel Alain , Machuron François , Karlin Lionel , Kolb Brigitte , Tiab Mourad , Araujo Carla , Meuleman Nathalie , Malfuson Jean-Valère , Bourquard Pascal , Lenain Pascal , Roussel Murielle , Jaccard Arnaud , Pétillon Marie-Odile , Belhadj-Merzoug Karim , Lepeu Gérard , Chrétien Marie-Lorraine , Fontan Jean , Rodon Philippe , Schmitt Anna , Offner Fritz , Voillat Laurent , Cereja Sophie , Kuhnowski Frédérique , Rigaudeau Sophie , Decaux Olivier , Humbrecht-Kraut Catherine , Frayfer Jamile , Fitoussi Olivier , Roos-Weil Damien , Eisenmann Jean-Claude , Dorvaux Véronique , Voog Eric G. , Attal Michel , Moreau Philippe , Avet-Loiseau Hervé , Hulin Cyrille , Facon Thierry
Published: April 2023

Supplementary Figure 1. Complementary survival curves for the whole cohort (n=30). (A) Event Free Survival (EFR); (B) Time to new treatment (TTNT); (C) Duration of response (DOR). Supplementary Figure 2. Progression Free Survival and Overall Survival according to cytogenetic risk (n=30). (A) PFS according to cytogenetic risk; (B) OS according to cytogenetic risk.
Figure S4 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Authors: Li Li , Jiang Liyan , Wang Yubo , Zhao Yizhuo , Zhang Xiao-Ju , Wu Guoming , Zhou Xiangdong , Sun Jianguo , Bai Jun , Ren Biyong , Tian Kun , Xu Zhi , Xiao Hua-liang , Zhou Qi , Han Rui , Chen Hengyi , Wang Haidong , Yang Zhenzhou , Gao Chan , Cai Shangli , He Yong
Published: April 2023

Dynamics of IL-6 levels in the two treatment groups at different time points (A) and comparison of the IL-6 levels between the two arms at each time point (B).
Supplementary Data from The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Authors: Truini Anna , Starrett Jacqueline H. , Stewart Tyler , Ashtekar Kumar , Walther Zenta , Wurtz Anna , Lu David , Park Jin H. , DeVeaux Michelle , Song Xiaoling , Gettinger Scott , Zelterman Daniel , Lemmon Mark A. , Goldberg Sarah B. , Politi Katerina
Published: April 2023

Supplementary Figure Legends
Figure S3 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Authors: Li Li , Jiang Liyan , Wang Yubo , Zhao Yizhuo , Zhang Xiao-Ju , Wu Guoming , Zhou Xiangdong , Sun Jianguo , Bai Jun , Ren Biyong , Tian Kun , Xu Zhi , Xiao Hua-liang , Zhou Qi , Han Rui , Chen Hengyi , Wang Haidong , Yang Zhenzhou , Gao Chan , Cai Shangli , He Yong
Published: April 2023

Impact of the IL-6 cutoff level on progression-free survival (A) and overall survival (B).
Table S5 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S5 shows the correlation between patients' clinicopathologic parameters and CD66b+ TINs in tumor parenchyma.
Table S4 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S4 shows the multivariate Cox regression analyses of overall survival.
Suppl Figure 7 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 7
Table S2 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S2 shows the univariate Cox regression analyses of disease free survival.
Figure S4 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Figure S4 shows that TINs promote EMT by a CD90-TIMP-1 juxtacrineparacrine. Loop
Suppl Figure 3 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 3
Figure S3 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Figure S3 shows that TINs promote metastasis by TIMP-1.
Supplementary Data from Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
Authors: O'Malley John T. , de Masson Adele , Lowry Elizabeth L. , Giobbie-Hurder Anita , LeBoeuf Nicole R. , Larocca Cecilia , Gehad Ahmed , Seger Edward , Teague Jessica E. , Fisher David C. , Kupper Thomas S. , Devlin Phillip M. , Clark Rachael A.
Published: April 2023

Figure S4
Supplementary figure 7 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Summary of the effects of IL-1B on breast cancer progression to metastasis and growth in the bone microenvironment.
Supplementary figure 6 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Effects of IL-1B on osteoclast and osteoblast activity in vivo.
Supplementary figure 5 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Suppression of IL-1 signalling affects bone integrity and vasculature.
Table S4 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Copy number alterations correlate with immunotherapy response in both Miao et al and our data
Table S3 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Influence of histology on survival analyses
Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Detailed individual characteristics of each patient
Supplementary Figures S1-8 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Supplementary Figures S1-8
Supplementary Table 1 from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Authors: Chen Robert , Herrera Alex F. , Hou Jessie , Chen Lu , Wu Jun , Guo Yuming , Synold Timothy W. , Ngo Vu N. , Puverel Sandrine , Mei Matthew , Popplewell Leslie , Yi Shuhua , Song Joo Y. , Tao Shu , Wu Xiwei , Chan Wing C. , Forman Stephen J. , Kwak Larry W. , Rosen Steven T. , Newman Edward M.
Published: April 2023

Supplementary Table 1
Figure S5 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Figure S5 shows changes in TNFα in plasma from screening thru day 9 at the indicated doses.
Figure S4 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Figure S4 shows changes in interleukin-10 in plasma from screening thru day 9 at the indicated doses.
Supplementary Data from High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
Authors: Sun Wen , Li Shi-Chao , Xu Li , Zhong Wei , Wang Zhen-Guang , Pan Chu-zhi , Li Jing , Jin Guang-Zhi , Ta Na , Dong Wei , Liu Dan , Liu Hui , Wang Hong-Yang , Ding Jin
Published: April 2023

Supplementary Data
Figure S1 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Figure S1 shows ASTX660 dose proportionality-power model analyses on AUC0-24 and Cmax by formulation.
Supplementary Tables S1 and S2 from FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults
Authors: Li Ruo-Jing , Jin Runyan , Liu Chao , Cao Xianhua , Manning Michael L. , Di Xu Michael , Przepiorka Donna , Namuswe Frances , Deisseroth Albert , Goldberg Kirsten B. , Blumenthal Gideon M. , Pazdur Richard
Published: April 2023

Supplementary Table S1. Grouped Terms Used In The Safety Analysis; Supplementary Table S2. Selected Grade > 3 Adverse Reactions by Treatment Phase in Study DFCI 11-001
Supplementary Data from Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Authors: de la Iglesia Janis V. , Slebos Robbert J.C. , Martin-Gomez Laura , Wang Xuefeng , Teer Jamie K. , Tan Aik Choon , Gerke Travis A. , Aden-Buie Garrick , van Veen Tessa , Masannat Jude , Chaudhary Ritu , Song Feifei , Fournier Michelle , Siegel Erin M. , Schabath Matthew B. , Wadsworth J. Trad , Caudell Jimmy , Harrison Louis , Wenig Bruce M. , Conejo-Garcia Jose , Hernandez-Prera Juan C. , Chung Christine H.
Published: April 2023

Supplementary Table 1_3_4_6_7_8
Table S1, Table S2, Table S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
Authors: Guindalini Rodrigo Santa Cruz , Zheng Yonglan , Abe Hiroyuki , Whitaker Kristen , Yoshimatsu Toshio F. , Walsh Tom , Schacht David , Kulkarni Kirti , Sheth Deepa , Verp Marion S. , Bradbury Angela R. , Churpek Jane , Obeid Elias , Mueller Jeffrey , Khramtsova Galina , Liu Fang , Raoul Akila , Cao Hongyuan , Romero Iris L. , Hong Susan , Livingston Robert , Jaskowiak Nora , Wang Xiaoming , Debiasi Marcio , Pritchard Colin C. , King Mary-Claire , Karczmar Gregory , Newstead Gillian M. , Huo Dezheng , Olopade Olufunmilayo I.
Published: April 2023

Table S1. Specifics of DCE-MRI Techniques Used; Table S2. Pathogenic mutations identified in study participants; Table S3. Patients' reasons of withdrawls from the study within 5 years
Supplementary Data from Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Authors: Ferrari Anna C. , Alumkal Joshi J. , Stein Mark N. , Taplin Mary-Ellen , Babb James , Barnett Ethan S. , Gomez-Pinillos Alejandro , Liu Xiaomei , Moore Dirk , DiPaola Robert , Beer Tomasz M.
Published: April 2023

Supplementary methods and Figure S1
Figure S4 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

Individual histograms of perforin expression by memory CD8 T cell cluster pre- and post-vaccination
Figure S05 from Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Authors: Hutchinson Katherine E. , Yost Susan E. , Chang Ching-Wei , Johnson Radia Marie , Carr Adrian R. , McAdam Paul R. , Halligan Daniel L. , Chang Chun-Chieh , Schmolze Daniel , Liang Jackson , Yuan Yuan
Published: April 2023

Line of treatment by immune gene signature scores, cell deconvolution analysis
Supplementary Methods from Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Authors: Weinmann Sheila , Leo Michael C. , Francisco Melanie , Jenkins Charisma L. , Barry Todd , Leesman Glen , Linke Steven P. , Whitworth Pat W. , Patel Rakesh , Pellicane James , Wärnberg Fredrik , Bremer Troy
Published: April 2023

Supplementary Methods
Figure S6 from High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy
Authors: Eranki Avinash , Srinivasan Priya , Ries Mario , Kim AeRang , Lazarski Christopher A. , Rossi Christopher T. , Khokhlova Tatiana D. , Wilson Emmanuel , Knoblach Susan M. , Sharma Karun V. , Wood Bradford J. , Moonen Chrit , Sandler Anthony D. , Kim Peter C.W.
Published: April 2023

Figure S6. Effect of Î±CTLA-4 + Î±PD-L1 only at 24 and 48 hrs after last checkpoint inhibitor dose on IFN-Æ".
Supplementary Figure S3 from Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Authors: Mitani Yoshitsugu , Lin Sue-Hwa , Pytynia Kristen B. , Ferrarotto Renata , El-Naggar Adel K.
Published: April 2023

Identification of salivary specific AR downstream targeted genes.
Figure S4 from High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy
Authors: Eranki Avinash , Srinivasan Priya , Ries Mario , Kim AeRang , Lazarski Christopher A. , Rossi Christopher T. , Khokhlova Tatiana D. , Wilson Emmanuel , Knoblach Susan M. , Sharma Karun V. , Wood Bradford J. , Moonen Chrit , Sandler Anthony D. , Kim Peter C.W.
Published: April 2023

Figure S4. Effect of HIFU alone at 24, 48 and 72 hrs on circulating cytokines.
Supplementary Data from Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Authors: Finn Richard S. , Liu Yuan , Zhu Zhou , Martin Miguel , Rugo Hope S. , Diéras Véronique , Im Seock-Ah , Gelmon Karen A. , Harbeck Nadia , Lu Dongrui R. , Gauthier Eric , Huang Bartlett Cynthia , Slamon Dennis J.
Published: April 2023

Supplementary material
Table S4 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplementary Table 4. Clinical outcomes for patients with CBF AML according to E8+ vs KIT- mutational status
Table S3 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplementary Table 3. Outcome for KIT E17+ mutation positive patients according to treatment arm (No GO vs. GO)
Table S3 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

Differentially expressed genes across all clusters
Figure S2 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplemental Figure 2. Functional Evaluation and TKI response of E11 mutations. (A) Evaluation of the phosphorylation status of KIT following transfection of the mutations in exon 11, V559D and L576P, into HEK293 cell line. (B) IL-3 independent growth following transduction into Ba/F3 cells. (C) pKIT response following dasatinib exposure in HEK293 cell line transfected with E11 V559D mutation. (D) pKIT response following crenolanib exposure in HEK293 cell line transfected with E11 V559D mutation. (E) pKIT response following dasatinib exposure in HEK293 cell line transfected with E11 L576P mutation. (F) pKIT response following crenolanib exposure in HEK293 cell line transfected with E11 V559D mutation.
Figure S1 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Authors: Tarlock Katherine , Alonzo Todd A. , Wang Yi-Cheng , Gerbing Robert B. , Ries Rhonda , Loken Michael R. , Pardo Laura , Hylkema Tiffany , Joaquin Jason , Sarukkai Leela , Raimondi Susana C. , Hirsch Betsy , Sung Lillian , Aplenc Richard , Bernstein Irwin , Gamis Alan S. , Meshinchi Soheil , Pollard Jessica A.
Published: April 2023

Supplemental Figure 1. (A) KIT mutational status of the cohort; (B) Prevalence of CBF subtype among the E8 and E17 mutations. (B) Among E8 mutations, 54% of patients were inv(16) and 46% were t(8;21). (C) Among E17 mutations, 37% of patients were inv(16) and 63% were t(8;21).
Supplemental legend from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

Supplemental legend
Supplementary Table 1 from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Authors: McMichael Elizabeth L. , Benner Brooke , Atwal Lakhvir S. , Courtney Nicholas B. , Mo Xiaokui , Davis Melanie E. , Campbell Amanda R. , Duggan Megan C. , Williams Kallan , Martin Kyle , Levine Kala , Olaverria Salavaggione Gonzalo N. , Noel Tiffany , Ganju Akaansha , Uppati Sarvani , Paul Bonnie , Olencki Thomas , Teknos Theodoros N. , Savvides Panos , Tridandapani Susheela , Byrd John C. , Caligiuri Michael A. , Liu Stephen V. , Carson William E.
Published: April 2023

Supplementary Table 1. Toxicities; Supplementary Table 2. Patient characteristics and response evaluation; Supplementary Table 3. Patient Correlative Study Results
Supplementary Figures from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Authors: McMichael Elizabeth L. , Benner Brooke , Atwal Lakhvir S. , Courtney Nicholas B. , Mo Xiaokui , Davis Melanie E. , Campbell Amanda R. , Duggan Megan C. , Williams Kallan , Martin Kyle , Levine Kala , Olaverria Salavaggione Gonzalo N. , Noel Tiffany , Ganju Akaansha , Uppati Sarvani , Paul Bonnie , Olencki Thomas , Teknos Theodoros N. , Savvides Panos , Tridandapani Susheela , Byrd John C. , Caligiuri Michael A. , Liu Stephen V. , Carson William E.
Published: April 2023

Supplemental Figure S1. Levels of serum cytokines in patients over the course of treatment. Serum levels of the cytokines IFN-γ (A), IP-10 (B), TNF-α (C) MIP-1α (D), MIP-1β (E), RANTES (F), GM CSF (G), and IL-8 (H) were measured at baseline and during cycle 8 using a custom V-Plex assay. Assay was performed in triplicate and the average was plotted for each individual patient. *, p=0.0008 for IFN-γ, p=0.0011 for IP-10, p=0.0102 for TNF-α Supplemental Figure S2. Levels of serum cytokines in patients stratified by length of progression-free survival. Serum levels of the cytokines MIP-1α (A), MIP-1β (B), RANTES (C), GM-CSF (D), and IL-8 (E) were measured at baseline and during cycle 8 using a custom V-Plex assay. The assay was performed in triplicate and the average was plotted for each individual patient stratified by progression-free survival greater than or less than 100 days Supplemental Figure S3. Gating strategy for defining monocytic and granulocytic MDSC. Examples of monocytic-dominant (A) and granulocytic-dominant (B) total MDSC. PBMCs procured from pre-therapy blood draws were stained with anti-CD33-APC, anti-HLA-DR-PECy7, anti-CD11b-PE, anti-CD14-V-450, and anti CD15-FITC antibodies; CD33+/HLA-DR- populations were further characterized by CD15, CD14, and CD11b expression. Percentages gleaned from CD15+CD11b+ and CD14+CD11b+ quadrants were back multiplied by total MDSC (CD33+HLA-DR-) to obtain values presented in Table S3.
Supplemental Table 1 from Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Authors: Juthani Rupa , Madajewski Brian , Yoo Barney , Zhang Li , Chen Pei-Ming , Chen Feng , Turker Melik Z. , Ma Kai , Overholtzer Michael , Longo Valerie A. , Carlin Sean , Aragon-Sanabria Virginia , Huse Jason , Gonen Mithat , Zanzonico Pat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron W.
Published: April 2023

Table reviewing nanoparticle drug delivery systems in brain tumor models
Supplemental Figure 6 from Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Authors: Juthani Rupa , Madajewski Brian , Yoo Barney , Zhang Li , Chen Pei-Ming , Chen Feng , Turker Melik Z. , Ma Kai , Overholtzer Michael , Longo Valerie A. , Carlin Sean , Aragon-Sanabria Virginia , Huse Jason , Gonen Mithat , Zanzonico Pat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron W.
Published: April 2023

Representative images of I-124-cRGD-C' dot uptake and distribution in primary human glioma; part of an ongoing Phase 1 trial
Figure S3 from lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP
Authors: Li Nan , Yang Guohua , Luo Liyun , Ling Li , Wang Xiaorong , Shi Lejuan , Lan Junsong , Jia Xiaoting , Zhang Qiong , Long Ze , Liu Jinbao , Hu Weimin , He Zhimin , Liu Haiying , Liu Wanqing , Zheng Guopei
Published: April 2023

Figure S3, related to Figure 3. THAP9-AS1 enables PDAC cells growth via enhancing YAP activation.
Supplemental Figure 4 from Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Authors: Juthani Rupa , Madajewski Brian , Yoo Barney , Zhang Li , Chen Pei-Ming , Chen Feng , Turker Melik Z. , Ma Kai , Overholtzer Michael , Longo Valerie A. , Carlin Sean , Aragon-Sanabria Virginia , Huse Jason , Gonen Mithat , Zanzonico Pat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron W.
Published: April 2023

Data demonstrating mechanism of dasatinib release and in vitro pathway inhibition
Table S2 from Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy
Authors: Hai Josephine , Zhang Hua , Zhou Jin , Wu Zhong , Chen Ting , Papadopoulos Eleni , Dowling Catríona M. , Pyon Val , Pan Yuanwang , Liu Jie Bin , Bronson Roderick T. , Silver Heather , Lizotte Patrick H. , Deng Jiehui , Campbell Joshua D. , Sholl Lynette M. , Ng Christine , Tsao Ming-Sound , Thakurdin Cassandra , Bass Adam J. , Wong Kwok-Kin
Published: April 2023

CRISPR/Cas9 guides, primers and sequencing results
Supplementary Figure 1 from Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Authors: Ribas Antoni , Daud Adil , Pavlick Anna C. , Gonzalez Rene , Lewis Karl D. , Hamid Omid , Gajewski Thomas F. , Puzanov Igor , Wongchenko Matthew , Rooney Isabelle , Hsu Jessie J. , Yan Yibing , Park Erica , McArthur Grant A.
Published: April 2023

Supplementary Figure 1
Table S4 from Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Authors: Yoon Harry H. , Shi Qian , Heying Erica N. , Muranyi Andrea , Bredno Joerg , Ough Faith , Djalilvand Azita , Clements June , Bowermaster Rebecca , Liu Wen-Wei , Barnes Michael , Alberts Steven R. , Shanmugam Kandavel , Sinicrope Frank A.
Published: April 2023

Table S4. Identification of optimal cutpoint in CD3+ T-cell densities at the invasive margin (CD3+IM) to distinguish overall survival in mismatch repair-deficient stage IIII colon cancers
Supplementary figure legends from Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8+ T-Cell–Dependent Tumor Activity
Authors: Watanabe Tsubasa , Gaedicke Simone , Guffart Elena , Firat Elke , Niedermann Gabriele
Published: April 2023

Supplementary figure legends